Site-directed PEGylation of human basic fibroblast growth factor

Area of Science:

• Biochemistry
• Protein Engineering
• Molecular Biology

Background:

• Human basic fibroblast growth factor (hbFGF) is crucial for cell growth and repair.
• Modifying hbFGF can alter its properties for therapeutic applications.
• PEGylation is a common technique to improve protein stability and pharmacokinetics.

Purpose of the Study:

• To develop a PEGylated hbFGF derivative with retained biological activity.
• To optimize the PEGylation process for hbFGF.
• To evaluate the mitogenic activity of the modified hbFGF.

Main Methods:

• Site-directed mutagenesis was used to create an hbFGF mutant (hbFGFSer25,69,92) with a single cysteine residue.
• Polyethylene glycol (PEG5K) was coupled to the hbFGF mutant via the cysteine residue.
• Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and ion exchange chromatography were used for analysis and purification.

Main Results:

• A PEGylated hbFGF derivative (PEG5K-hbFGFSer25,69,92) was successfully synthesized with an 80% modification extent.
• The optimal PEGylation conditions were determined (4°C, 4h, 20:1 molar ratio).
• The purified PEG5K-hbFGFSer25,69,92 retained approximately 60% of the mitogenic activity of the hbFGF mutant.

Conclusions:

• PEGylation of hbFGF is feasible while preserving significant mitogenic activity.
• The PEGylated hbFGF derivative is a promising candidate for further in vivo bioactivity studies.
• This work provides a foundation for developing improved FGF-based therapeutics.